BioAsia 2026 Concludes with Record 4500 Delegates and 4000 B2B Meetings

Key facts

• BioAsia 2026, the 23rd edition of Asia’s premier life sciences and health-tech forum, concluded in Hyderabad with over 4500 delegates and 4000 high-impact B2B meetings.
• The event theme was ‘TechBio Unleashed: AI, Automation, and the Biology Revolution’.
• More than 120 startups were shortlisted and 40+ most innovative startups exhibited solutions in MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers.
• BioAsia 2026 Innovation Awards were presented to Achala Health Services Private Limited, Exquinz Life Sciences Pvt Ltd, Helex, Natural Solutions & Nutraceuticals Pvt Ltd, and Sree Guravey Life Sciences OPC Pvt Ltd.
• Achala Health Services Private Limited is building India’s first healthcare-focused Small Language Model (SLM) that automates hospital workflows and integrates with EMR, LIMS, RIS, HIS, and pharmacy data.
• Exquinz Life Sciences Pvt Ltd integrates next-generation digital vaccine vial monitors with AI-enabled authentication and real-time tracking to predict residual vaccine shelf-life and reduce wastage.
• Helex develops non-viral gene therapies for renal diseases using a proprietary kidney-targeting lipid nanoparticle to restore PKD1 gene expression for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
• Natural Solutions & Nutraceuticals Pvt Ltd offers Virulina, a triple-action herbal product targeting respiratory viruses, with patent-protected antiviral, immunomodulatory, and anti-inflammatory properties.
• Sree Guravey Life Sciences OPC Pvt Ltd develops BioMap Markers for biopsy procedures that are ultrasonography-sensitive, biocompatible, non-calcified, and metal-free to ensure accurate placement and diagnostic outcomes.